Sofinnova Partners, an independent venture capital firm, led a $138m Series C funding round in Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, with participation from ICG, Tekla Capital, CTI Life Sciences Andera Partners, Novo Ventures, Kurma Partners, EQT, Bpifrance Investissement, Sectoral Asset Management, Pontifax, Orbimed, Mass General Brigham Ventures, ATEM, Credit Agricole and Turenne Capital. “We are very pleased to complete this large Series C financing, which will enable us to build on our momentum with eneboparatide and accelerate the growth of Amolyt Pharma and its pipeline globally. We are thankful to Sofinnova Partners and ICG for co-leading this financing round, and to all our new and existing investors for their confidence in our team and for their support of our strategy to build a global and sustainable rare disease company. This investment will allow us to continue working tirelessly on bringing novel, life-changing treatments to patients with rare endocrine and related diseases," Thierry Abribat, Amolyt Pharma Founder and CEO.